Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma

BACKGROUND: Cancer cachexia is characterised by skeletal muscle wasting; however, potential for muscle anabolism in patients with advanced cancer is unproven. METHODS: Quantitative analysis of computed tomography images for loss/gain of muscle in cholangiocarcinoma patients receiving selumetinib (AZ...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Prado, C M M, Bekaii-Saab, T, Doyle, L A, Shrestha, S, Ghosh, S, Baracos, V E, Sawyer, M B
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2012
Matèries:
Short Communication
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3349178/
https://ncbi.nlm.nih.gov/pubmed/22510747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.144
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars